In addition, Zhang et al. (176) used a lentiviral vector to transduce CAIX-specific third-generation CAR into NK92 cells and evaluated the immune effect of CAR-NK92 cells against CAIX-positive RCC cells in vitro, and found that the cytotoxicity of CAR-NK92 cells was enhanced after RCC cells were treated with bortezomib. This evidence concerns the gene CA9 and renal cell adenocarcinoma.